Compare Cytokinetics Inc (CYTK) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs General Dynamics Corporation — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while General Dynamics Corporation trades at $328.74 (market cap $89.26B). The key difference: General Dynamics Corporation is far larger — about 10.4× Cytokinetics Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and General Dynamics Corporation for 85 Days on average.
| CYTK | GD | |
|---|---|---|
Market Cap | $8.62B | $89.26B |
Volume | 2,594,626 | 1,496,273 |
Sector | Health | Industrials |
52-Week High | $87.26 | $395.97 |
52-Week Low | $54.76 | $312.53 |
Typical Hold Time | 19 Days | 85 Days |
Enterprise Value | $8.72B | $94.40B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
General Dynamics (GD) trades at $326.63, down 1.42% amid bearish technical signals, though fundamentals remain solid with consistent earnings beats and strong defense contract visibility. The stock shows oversold RSI readings while maintaining healthy profitability metrics including 8.18% net margin and 17.8% ROE. Recent Pentagon spending focus and dividend stability support the investment case despite near-term price pressure.
GD presents a compelling value opportunity with 57% analyst buy ratings and $420.57 consensus target representing 29% upside. Defense budget tailwinds and submarine/vehicle demand provide growth catalysts, though technical weakness and defense sector volatility pose near-term risks. The company's consistent cash flow generation and dividend payments offer stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
